Latest peptide research & news
Automatically aggregated from PubMed and biotech/pharma news feeds (FiercePharma, ScienceDaily), filtered to peptide-relevant stories. These link out to the original publishers — they are not authored by this site and are not an endorsement.
PubMed · peer-reviewed
A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy
Ampofo E et al. · Obesity science & practice · 2026 Oct
Read at sourceAssociation of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study
Karanxha J et al. · International journal of cardiology · 2026 Sep 8
Read at sourceDevelopment of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction
Khopade AJ et al. · Pharmaceutical development and technology · 2026 Sep 8
Read at sourceEngineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling
Lu L et al. · ACS applied materials & interfaces · 2026 Sep 8
Read at sourceTirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study
Waki H et al. · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 8
Read at sourceWeight Loss without Food Intake Suppression through Size-Dependent Retention of Anti-Inflammatory Nanomedicines
Medina NG et al. · ACS nano · 2026 Sep 8
Read at sourceMonitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy
Xu X et al. · Analytical chemistry · 2026 Sep 8
Read at sourceCoordination chemistry and antimicrobial activity of LL-37, its C-terminal fragment, and a peptidomimetic analogue
Szarszoń K et al. · Dalton transactions (Cambridge, England : 2003) · 2026 Sep 8
Read at sourcePhosphate homeostasis in pediatrics: The pubertal transition to tighter hormonal control
Giannakopoulos A et al. · Bone · 2026 Sep 7
Read at sourceUrinary Sclerostin and Renal Magnesium Handling in Proteinuric Non-Diabetic Chronic Kidney Disease
Wu CF et al. · Kidney & blood pressure research · 2026 Sep 7
Read at sourceScreening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis
Noureddin M et al. · JHEP reports : innovation in hepatology · 2026 Sep 7
Read at sourceImprovement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist
Blitshteyn S et al. · Immunopharmacology and immunotoxicology · 2026 Sep 6
Read at sourceHIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signaling
Wang S et al. · Pharmacological research · 2026 Sep 6
Read at sourceEmerging antimicrobial peptides in gastrointestinal disorders: Dual role in immunity and therapy
Selvaraj K et al. · World journal of gastrointestinal pharmacology and therapeutics · 2026 Sep 5
Read at sourceModerated mediation of cerebrospinal fluid fibroblast growth factor 21 and KLB rs17618244 genotype in the association between educational attainment and cognitive function
Lin J et al. · Behavioural brain research · 2026 Sep 5
Read at sourceEffects of Heidihuang Pill on renal fibrosis and senescence-associated changes in rats with unilateral ureteral obstruction: A fecal metabolomics and Klotho-knockdown study
He G et al. · Journal of ethnopharmacology · 2026 Sep 5
Read at sourceSerum soluble klotho in the Systolic Blood Pressure Intervention Trial: comparison of two assays and correlation with kidney and mineral metabolism biomarkers
Drew DA et al. · Clinical kidney journal · 2026 Sep
Read at sourceThe Evolution of Medications for Obesity Management
Gill J et al. · JGH open : an open access journal of gastroenterology and hepatology · 2026 Sep
Read at sourceComparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA
Tian Z et al. · EClinicalMedicine · 2026 Sep
Read at sourceEfficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials
Hageen AW et al. · Endocrinology, diabetes & metabolism · 2026 Sep
Read at sourceTargeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress
Xiao D et al. · Physiological research · 2026 Aug 31
Read at sourceTirzepatide-Based Therapy for Multidomain Metabolic Improvement in an Active Duty Service Member: A Case Report
Kim SK · Cureus · 2026 Aug
Read at sourceOff-label semaglutide: A call for monitoring protocols in non-obese populations
Rehman M · JPMA. The Journal of the Pakistan Medical Association · 2026 Aug
Read at sourceKlotho G-395A Polymorphism as a Risk Factor for Atrial Fibrillation in Patients on Maintenance Hemodialysis
Zhang Y et al. · Advances in urology · 2026
Read at sourceSalivary cathelicidin LL-37 as a non-invasive biomarker for oral cancer detection
Ravichandran T et al. · Bioinformation · 2026
Read at sourceBiotech & pharma · recent coverage
Ozempic and Wegovy may have an unexpected mental health benefit
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% low
Read at sourceNovo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after receiving the GLP-1 drug for 68 weeks.
Read at sourceThe Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo grow scripts
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to
Read at source